Thyroid Cancer Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017

News provided by

Oct 25, 2017, 09:02 ET

LONDON, Oct. 25, 2017 /PRNewswire/ -- Thyroid Cancer clinical trials report from VPA Research provides comprehensive analysis and trends in global Thyroid Cancer disease clinical trials. The research work analyzes the evolution of Thyroid Cancer clinical trial trends across countries and regions.

Download the full report: https://www.reportbuyer.com/product/5158750

The report focuses on drugs and therapies being evaluated for Thyroid Cancer treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Thyroid Cancer clinical trials.

Major drugs under development in Thyroid Cancer are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.

Scope of the Report-
- Number of Thyroid Cancer clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
- Trial information by Phase and Subjects recruited
- Trial information by status, type, sponsor type
- Drugs used for treatment of Thyroid Cancer
- Both observational and interventional trials analyzed
- Success rates of trials are analyzed
- Trends in enrollment over the past ten years identified
- Leading sponsors of Thyroid Cancer clinical trials worldwide are listed

Reasons to Buy-
- Track competition and design competitive advantages
- Identify right partners to associate with for further research
- Evaluate potential opportunities available in further clinical trials of the disease
- Formulate business development strategies through success rates of clinical trials
- Identify quick markets for recruiting subjects based on trials count by each market

Executive Summary

Thyroid Cancer is the cancer type originating in Thyroid gland. Though specific causes are not determined, the cancer occurs when thyroid cells undergo mutations, making cells to increase rapidly in count and size, forming tumors.

Types-
Thyroid Cancer is categorized into three main types –

Differentiated Thyroid Cancer
Papillary
Follicular
Hurthle
Medullary Thyroid Cancer
Sporadic
Familial
Anaplastic Thyroid Cancer

Stages-
Stage I - Tumor less than 2 cm
Stage II - Tumor between 2 cm and 4 cm
Stage III - Tumor more than 4 cm, or grown slightly beyond thyroid
Stage IVa- Tumor expands into nearby neck tissues/ some lymph nodes/ upper chest
Stage IVb- tumor expands to spine/ blood vessels
Stage IVC: Tumor might be spread to distant sites of body

Drugs in Clinical Trials Development in Thyroid Cancer include-
Adalimumab
Afatinib
Aldesleukin
Alectinib
Alendronate Sodium
Alfacalcidol
Anlotinib
Apatinib
Atezolizumab
Avelumab
Azacitidine
AZD4547
AZD5363
Bevacizumab
Binimetinib
Bojung-ikgitang
Buparlisib
Cabozantinib
Calcium Aluminosilicate
carboplatin
Cediranib Maleate
Ceritinib
Cholecystokinin
Cisplatin
Cobimetinib
Crizotinib
Crolibulin
Cyclophosphamide
Dabrafenib
Dasatinib
Defactinib
dexamethasone
Docetaxel
Dovitinib
Doxepin Hydrochloride
Doxorubicin
durvalumab
efatutazone
Entrectinib
Etoposide
Everolimus
Ferumoxytol
Fibrinogen Human
Fludarabine
Fosbretabulin
Gallium-68-IMP-288
gemcitabine
GSK2636771
IACS-010759
Ifosfamide
Iobenguane
Ipilimumab
Lapatinib
Larotrectinib
Lenalidomide
Lenvatinib
Levothyroxine
lidocaine
Liothyronine
Lipoic Acid
LOXO-195
LOXO-292
Metformin
minodronic acid
Nab-Paclitaxel(Abraxane)
nanocurcumin
Neratinib
Nintedanib
Nivolumab
Octreotide Acetate
Ofranergene obadenovec
Olaparib
omeprazole
Osimertinib
oxaliplatine
Paclitaxel
Palbociclib
Panobinostat
Pasireotide
pazopanib
Pembrolizumab
PF-04518600
Pilocarpine
Pioglitazone
PLX8394
Ponatinib
Pseudomonas Aeruginosa
Ranitidine
Regorafenib
Rosiglitazone
Rovalpituzumab tesirine
Sacituzumab govitecan
Sapanisertib
Selumetinib
Sirolimus
Sorafenib
Sulfatinib
Sunitinib Malate
TAEST16001
Taselisib
Tc 99m pertechnetate
temsirolimus
Tetrafluoroborate
TF 2
Thyrotropin alfa
Tipifarnib
Trametinib
tremelimumab
Utomilumab
Valproic Acid
Vandetanib
vemurafenib
[18 F]-6-L-fluorodihydroxyphenylalanine
111In-CP04
18F-Fludeoxyglucose
68Ga DOTATATE
99Tc-Methylenediphosphonate

Download the full report: https://www.reportbuyer.com/product/5158750

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
https://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com